JASPER THERAPEUTICS, INC. Financing Cash Flow
JASPER THERAPEUTICS, INC. (JSPR) reported Financing Cash Flow of $9.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-14
- JASPER THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$340.00K, a 198.55% decline year-over-year.
- JASPER THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $28.39M, a 315322.22% increase year-over-year.
- JASPER THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2024-12-31 was $345.00K.
- JASPER THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2024-09-30 was $9.00K, a 75.00% decline year-over-year.
- JASPER THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $34.21M, a 28.55% decline from fiscal 2024.
- JASPER THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2024 was $47.88M, a 52.58% decline from fiscal 2023.
- JASPER THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2023 was $100.97M, a 183483.64% increase from fiscal 2022.
- JASPER THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2022 was $55.00K, a 99.95% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 5 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $9.00K 10-Q · filed 2026-08-14 | ||||
| 2025-12-31 | -$340.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $28.05M derived: sum of 2 quarters · filed 2026-03-30 | $34.21M 10-K · filed 2026-03-30 | ||
| 2025-09-30 | $28.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $34.55M 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $6.16M 10-Q · filed 2026-08-14 | ||||
| 2024-12-31 | $345.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $354.00K derived: sum of 2 quarters · filed 2026-03-30 | $535.00K derived: sum of 3 quarters · filed 2026-03-30 | $47.88M 10-K · filed 2026-03-30 | |
| 2024-09-30 | $9.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $190.00K derived: sum of 2 quarters · filed 2025-11-10 | $47.54M 10-Q · filed 2025-11-10 | $47.27M derived: sum of 4 quarters · filed 2025-11-10 | |
| 2024-06-30 | $181.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $47.53M 10-Q · filed 2025-08-13 | $47.26M derived: sum of 3 quarters · filed 2025-08-13 | $47.30M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $47.35M 10-Q · filed 2025-05-12 | $47.08M derived: sum of 2 quarters · filed 2025-05-12 | $47.11M derived: sum of 3 quarters · filed 2025-05-12 | $46.81M derived: sum of 4 quarters · filed 2025-05-12 | |
| 2023-12-31 | -$271.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$235.00K derived: sum of 2 quarters · filed 2025-02-28 | -$540.00K derived: sum of 3 quarters · filed 2025-02-28 | $100.97M 10-K · filed 2025-02-28 | |
| 2023-09-30 | $36.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$269.00K derived: sum of 2 quarters · filed 2024-11-07 | $101.24M 10-Q · filed 2024-11-07 | $101.27M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | -$305.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $101.21M 10-Q · filed 2024-08-13 | $101.23M derived: sum of 3 quarters · filed 2024-08-13 | $101.23M derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | $101.51M 10-Q · filed 2024-05-14 | $101.54M derived: sum of 2 quarters · filed 2024-05-14 | $101.54M derived: sum of 3 quarters · filed 2024-05-14 | $101.55M derived: sum of 4 quarters · filed 2024-05-14 | |
| 2022-12-31 | $28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $29.00K derived: sum of 2 quarters · filed 2024-03-05 | $42.00K derived: sum of 3 quarters · filed 2024-03-05 | $55.00K 10-K · filed 2024-03-05 | |
| 2022-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $14.00K derived: sum of 2 quarters · filed 2023-11-09 | $27.00K 10-Q · filed 2023-11-09 | -$882.00K derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | $13.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $26.00K 10-Q · filed 2023-08-11 | -$883.00K derived: sum of 3 quarters · filed 2023-08-11 | $90.84M derived: sum of 4 quarters · filed 2023-08-11 | |
| 2022-03-31 | $13.00K 10-Q · filed 2023-05-12 | -$896.00K derived: sum of 2 quarters · filed 2023-05-12 | $90.83M derived: sum of 3 quarters · filed 2023-05-12 | $90.23M derived: sum of 4 quarters · filed 2023-05-12 | |
| 2021-12-31 | -$909.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $90.82M derived: sum of 2 quarters · filed 2023-03-08 | $90.22M derived: sum of 3 quarters · filed 2023-03-08 | $100.97M 10-K · filed 2023-03-08 | |
| 2021-09-30 | $91.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $91.13M derived: sum of 2 quarters · filed 2022-11-10 | $101.88M 10-Q · filed 2022-11-10 | $112.68M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | -$600.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $10.15M 10-Q · filed 2022-08-12 | $20.95M derived: sum of 3 quarters · filed 2022-08-12 | ||
| 2021-03-31 | $10.75M 10-Q · filed 2022-05-12 | $21.55M derived: sum of 2 quarters · filed 2022-05-12 | |||
| 2020-12-31 | $10.80M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $11.29M 10-K · filed 2022-03-18 | |||
| 2020-09-30 | $484.00K 10-Q · filed 2021-11-12 | ||||
| 2019-12-31 | $101.58M 10-K/A · filed 2021-05-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |